Day: September 10, 2021

TORONTO, Sept. 10, 2021 (GLOBE NEWSWIRE) — WPT Industrial Real Estate Investment Trust (the “REIT”) (TSX: WIR.U; WIR.UN – OTCQX: WPTIF) today announced the mailing of its management information circular (the “Circular”) and related materials for the special meeting (the “Meeting”) of the REIT’s unitholders (the “Unitholders”) to consider the previously announced plan of arrangement (the “Arrangement”) pursuant to which an affiliate of Blackstone Real Estate Income Trust, Inc. would acquire all of the outstanding trust units of the REIT (each, a “Unit”) through a series of transactions that would result in Unitholders receiving US$22.00 per Unit in cash (the “Consideration”), subject to applicable withholdings (the “Transaction”), all as more particularly described in the Circular. Recommendation of the Board of Trustees After...

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of second quarter initial public offering additions, effective Sept. 20, 2021. The stock will also be automatically added to the appropriate growth and value indexes. “On the heels of our successful IPO, the addition of Monte Rosa to the Russell 2000 and Russell 3000 Indexes serves as a significant milestone for the company as we advance our pipeline of novel molecular glues and continue the development of our unique and proprietary QuEENTM platform,” said Ajim Tamboli, CFA, Chief Financial Officer. “We are pleased to be part of the Russell indexes and look forward to broadening...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Sept. 10, 2021 (GLOBE NEWSWIRE) —  Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the filing of the Company’s unaudited interim financial statements for the three- and six-month period ended June 30, 2021, accompanying management’s discussion and analysis and related certifications ‎‎(collectively, the “Documents”) and provides a corporate update. Electronic copies of the Documents are available on SEDAR (www.sedar.com)...

Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines LEXINGTON, Mass. and BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections today announced the launch of SaponiQx, a subsidiary of Agenus, dedicated to driving innovation in novel adjuvant discovery and vaccine design, and its partnership with Ginkgo Bioworks, Inc. (“Ginkgo”), the leading horizontal platform for cell programming. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), is enabling customers across industries to improve products and manufacturing processes,...

PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 September 2021) Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announced that management will present at the following investor conferences in September.H.C. Wainwright 23rd Annual Global Investment ConferenceFireside Chat available on demand starting at 7:00 a.m. ET on Monday, September 13, 2021Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Fireside Chat: Wednesday, September 22, 2021 at 2:05 p.m. ETThe investor conferences will each be held...

      COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the research scientist and film-maker, as a full-time consultant, who will be working primarily at the COMPASS Discovery Center, based at University of the Sciences in Philadelphia (USciences) in the United States. Mr Morris will be advising COMPASS on research related to new psychedelic compounds that could be developed into therapies in areas of unmet mental health need. Hamilton Morris is the creator and director of the documentary series Hamilton’s Pharmacopeia, in which he investigates the chemistry, history, and cultural impact of various psychoactive drugs. He also carries out chemistry research at USciences, alongside the COMPASS...

CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of an inducement award outside of the Company’s 2019 Stock Incentive Plan to Mel Hayes, the Company’s newly appointed Chief Commercial Officer. The grant was approved by the Compensation Committee on August 4, 2021 as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consisted of a nonstatutory option to purchase up to 140,000 shares of common stock. The option has an exercise price of $28.49 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on...

Charlotte, N.C., Sept. 10, 2021 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that senior management will attend the 23rd Annual HC Wainwright Global Investment Conference on Tuesday, September 14, 2021. Meetings will take place virtually given the ongoing call for social distancing due to the Covid-19 pandemic. Investors that would like to schedule a meeting with Akoustis management should contact their HC Wainwright representative or Akoustis’ investor relations at ir@akoustis.com. Akoustis is actively delivering volume production of its WiFi 6 tandem filter solutions, shipping multiple 5G small cell XBAWTM filter solutions,...

TORONTO, Sept. 10, 2021 (GLOBE NEWSWIRE) — GameSquare Esports Inc. (CSE: GSQ; FRA: 29Q1) (the “Company”), an international gaming and esports company, announces a change to the location of its annual and special meeting to be held on September 21, 2021, at 10:00 a.m. EST (the “Meeting”). The new location for the Meeting will be Suite 1008, 150 York Street, Toronto, ON. There is no change in the date or time of the Meeting. Due to the ongoing COVID-19 pandemic and to mitigate potential risks to public health and safety, access to the Meeting will be limited to essential personnel and others entitled to attend the Meeting, subject to capacity and other restrictions. The Company has organized a webcast of the Meeting whereby shareholders can listen to the Meeting live online at http://services.choruscall.ca/links/gamesquare20210921.html....

Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophrenia Live webcast scheduled for Thursday, Oct. 7 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a virtual R&D event on Thursday, Oct. 7 from 10:00 to 11:30 a.m. ET. Hosted in a live webcast format, Cerevel will lead a discussion focused on CVL-871, a D1/D5 partial agonist for dementia-related apathy, as well as provide an update on CVL-231, its M4 positive allosteric modulator in development for the treatment of schizophrenia. This R&D event...